BCL2L1 and urinary bladder carcinoma: Overexpression of GRIM19 potentiated cisplatin sensitivity and reduced the invasion and proliferation of bladder cancer cells, which was due to attenuation of Bcl-xL polyubiquitination and degradation (85).